Phaseline

Companies › Curasight

Curasight: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
64Cu-DOTA-AE105
uPAR-targeting PET imaging agent; copper-64 labeled peptide for PET imaging of uPAR-expres
PLAURPhase 2Prostate CancerJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT0647480664Cu-DOTA-AE105Phase 2Prostate CancerOncologyJan 2027

Targets

PLAUR (1)

Companies with the same targets

Adcendo ApS

Companies built like this

Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.